$6.96
0.72% today
Nasdaq, Jan 06, 09:14 pm CET
ISIN
US8162121045
Symbol
RNAC

Cartesian Therapeutics Stock price

$6.91
+0.03 0.44% 1M
-3.86 35.84% 6M
-0.30 4.16% YTD
-10.72 60.81% 1Y
-10.49 60.29% 3Y
-36.89 84.22% 5Y
-203.09 96.71% 10Y
-203.09 96.71% 20Y
Nasdaq, Closing price Mon, Jan 05 2026
+0.15 2.22%
ISIN
US8162121045
Symbol
RNAC
Industry

Key metrics

Basic
Market capitalization
$179.7m
Enterprise Value
$36.3m
Net debt
positive
Cash
$143.4m
Shares outstanding
26.0m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
93.1 | 89.6
EV/Sales
18.8 | 18.1
EV/FCF
negative
P/B
negative
Financial Health
Equity Ratio
-1.6%
Return on Equity
1,138.3%
ROCE
-25.5%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$1.9m | $2.0m
EBITDA
$-88.7m | -
EBIT
$-91.5m | $-89.9m
Net Income
$-50.6m | $-62.2m
Free Cash Flow
$-68.9m
Growth (TTM | estimate)
Revenue
-96.0% | -94.8%
EBITDA
-68.7% | -
EBIT
-71.0% | -147.5%
Net Income
79.7% | 19.7%
Free Cash Flow
-42.3%
Margin (TTM | estimate)
Gross
-
EBITDA
-4,600.9% | -
EBIT
-4,748.2%
Net
-2,626.2% | -3,100.9%
Free Cash Flow
-3,575.4%
More
EPS
$-1.9
FCF per Share
$-2.6
Short interest
22.6%
Employees
66
Rev per Employee
$590.0k
Show more

Is Cartesian Therapeutics a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,084 stocks worldwide.

Cartesian Therapeutics Stock Analysis

Unlock Scores for Free

Analyst Opinions

15 Analysts have issued a Cartesian Therapeutics forecast:

12x Buy
80%
3x Hold
20%

Analyst Opinions

15 Analysts have issued a Cartesian Therapeutics forecast:

Buy
80%
Hold
20%

Financial data from Cartesian Therapeutics

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
1.93 1.93
96% 96%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 30 30
33% 33%
1,573%
- Research and Development Expense 55 55
2% 2%
2,832%
-89 -89
69% 69%
-4,594%
- Depreciation and Amortization 2.84 2.84
202% 202%
147%
EBIT (Operating Income) EBIT -91 -91
71% 71%
-4,741%
Net Profit -51 -51
80% 80%
-2,622%

In millions USD.

Don't miss a Thing! We will send you all news about Cartesian Therapeutics directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Cartesian Therapeutics Stock News

Neutral
GlobeNewsWire
about 9 hours ago
FREDERICK, Md., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the granting of inducement awards to two new employees. On January 2, 2026, the Company issued to these employees options to purchase an aggregate of 7,350 shares of the Company's co...
Neutral
GlobeNewsWire
19 days ago
FREDERICK, Md., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the appointment of Adrian Bot, M.D., Ph.D., to the Company's Board of Directors. Dr. Bot is a biopharma executive with three decades of experience in research and development (R&D) w...
Positive
Seeking Alpha
about 2 months ago
Cartesian Therapeutics (RNAC) is maintained at a "Buy" rating, driven by progress in its Descartes-08 mRNA CAR-T pipeline for autoimmune disorders. RNAC's phase 3 AURORA study targets AChR Ab+ myasthenia gravis, with positive long-term phase 2b data supporting ongoing late-stage development. Positive signals in systemic lupus erythematosus prompted RNAC to prioritize myositis, an underserved ma...
More Cartesian Therapeutics News

Company Profile

Selecta Biosciences, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. It produces the Synthetic Vaccine Particles (SVP) platform for immune tolerance and immune stimulation. The firm's proprietary pipeline includes SVP-enabled enzyme, oncology and gene therapies. The company was founded by Omid C. Farokhzad, Robert S. Langer Jr., and Ulrich von Andrian in 2007 and is headquartered in Watertown, MA.

Head office United States
CEO Carsten Brunn
Employees 66
Founded 2007
Website www.cartesiantherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today